Ani Pharmaceuticals Inc. (ANIP)
Zacks Industry Outlook Arcutis, Amicus and ANI
Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.
5 Biotech Stocks to Watch for Potential Upside
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
ANI (ANIP) Loses 15% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for ANI (ANIP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
